GO:0043518 negative regulation of DNA damage response, signal transduction by p53 class mediator: Tumor Suppression Checkpoint, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043518 describes the biological process that stops or reduces the p53-mediated DNA damage response, acting as a brake on the tumor suppressor pathway.
• HIC1 is a key transcriptional repressor that recruits corepressors to silence p53 target genes, thereby negatively regulating p53 signal transduction.
• Dysregulation of this process is linked to breast cancer risk, where gene expression profiles reveal altered DNA damage response networks.
• In hepatocellular carcinoma, CAMK1 phosphoinositide signaling intersects with protein sorting and transport networks that can modulate DNA damage responses.
• Experimental models for studying GO:0043518 include knockout, point-mutation, knock-in, and overexpression cell lines, as well as CRISPR library screening.
• Understanding this negative regulation is critical for cancer therapy, as restoring or inhibiting the brake can sensitize tumors to DNA-damaging agents.
Description
The p53 tumor suppressor is a central node in the DNA damage response, but its activity must be tightly controlled to avoid excessive cell death or senescence. GO:0043518, negative regulation of DNA damage response, signal transduction by p53 class mediator, defines the processes that attenuate or shut down p53 signaling after DNA damage. This regulation is essential for normal tissue homeostasis and its disruption contributes to cancer and other diseases. Researchers study this term to identify molecular brakes on p53, such as transcriptional corepressors and signaling modulators, that could be targeted therapeutically. The QuickGO definition states: Any process that stops, prevents, or reduces the frequency, rate or extent of the cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage. This article synthesizes published findings on the genes, mechanisms, and experimental approaches relevant to GO:0043518.
negative regulation of DNA damage response, signal transduction by p53 class mediator At A Glance
| GO ID | GO:0043518 |
|---|---|
| GO term | negative regulation of DNA damage response, signal transduction by p53 class mediator |
| Ontology | biological_process |
| Synonym | down regulation of DNA damage response, signal transduction by p53 class mediator; down-regulation of DNA damage response, signal transduction by p53 class mediator; downregulation of DNA damage response, signal transduction by p53 class mediator; inhibition of DNA damage response, signal transduction by p53 class mediator; negative regulation of p53 induced by DNA damage response |
| Major function | Attenuation or termination of p53-mediated DNA damage signaling to prevent excessive cell death or senescence |
| Related genes | HIC1, CAMK1, and other modulators of p53 signaling |
| Disease relevance | Cancer (breast, hepatocellular carcinoma), where dysregulation promotes tumorigenesis |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, library screening, bioinformatics |
What Is GO:0043518?
GO:0043518 encompasses any cellular process that negatively regulates the signal transduction cascade initiated by p53 (or its equivalent) following DNA damage detection. In other words, it is the set of molecular events that put the brakes on p53-mediated responses such as cell cycle arrest, apoptosis, or senescence. This includes transcriptional repression of p53 target genes, post-translational modifications that inactivate p53, and signaling cross-talk that dampens the DNA damage response.
Why Is negative regulation of DNA damage response, signal transduction by p53 class mediator Important in Cell Biology?
GO:0043518 is critical because it provides a counterbalance to p53 activation, ensuring that DNA damage responses are proportionate and reversible. Without this negative regulation, cells may undergo unwarranted apoptosis or senescence, contributing to tissue degeneration; conversely, loss of this brake can lead to unchecked p53 activity or, paradoxically, promote cancer by allowing cells with damaged DNA to survive. Understanding the molecular players in this process offers therapeutic opportunities to modulate p53 signaling in cancer and other diseases.
• Prevents excessive p53-mediated apoptosis or senescence after DNA damage.
• Maintains tissue homeostasis and prevents degenerative diseases.
• Its dysregulation is implicated in breast cancer risk and progression.
• Modulates hepatocellular carcinoma signaling networks involving CAMK1.
• Provides targets for sensitizing tumors to chemotherapy or radiotherapy.
• Helps explain resistance to p53-targeted therapies.
• Involved in cellular stress responses and protein sorting pathways.
• Can be studied using CRISPR-based functional genomics.
• Relevant to understanding single-nucleotide polymorphisms in HIC1 that affect p53 regulation.
• Offers biomarkers for cancer susceptibility and prognosis.
What Happens During negative regulation of DNA damage response, signal transduction by p53 class mediator?
Initiation of p53 Activation
In simple terms: When DNA is damaged, p53 is turned on to stop the cell cycle or trigger repair.
DNA damage sensors such as ATM and ATR activate p53 through phosphorylation, leading to stabilization and transcriptional activation of target genes like CDKN1A (p21) and MDM2. This initial response is the substrate for negative regulation described by GO:0043518.
Recruitment of Transcriptional Corepressors
In simple terms: Proteins like HIC1 bind to p53 target genes and shut them off.
HIC1 (hypermethylated in cancer 1) is a transcriptional repressor that recruits corepressor complexes (e.g., CtBP, N-CoR) to p53-responsive promoters, thereby reducing p53-mediated transactivation. Computational analysis of HIC1 SNPs reveals variants that may impair this repression, linking to altered p53 signaling.
Post-translational Inactivation of p53
In simple terms: Chemical modifications can tag p53 for degradation or keep it out of the nucleus.
MDM2 and other E3 ubiquitin ligases ubiquitinate p53, targeting it for proteasomal degradation, which effectively terminates the DNA damage response. Additionally, phosphatases can remove activating phosphorylations, further dampening the signal.
Cross-talk with Other Signaling Pathways
In simple terms: Other cellular signals can interfere with p53 to reduce its activity.
CAMK1 phosphoinositide signaling influences protein sorting and transport networks in hepatocellular carcinoma, which may indirectly modulate p53 localization and function. Such cross-talk represents a layer of negative regulation that fine-tunes the DNA damage response.
Resolution and Recovery
In simple terms: Once damage is repaired, the brakes are applied so the cell can return to normal.
After DNA repair, negative feedback loops involving p53 itself (e.g., MDM2 induction) and other repressors ensure that p53 activity declines, allowing cell cycle re-entry and survival. Failure of this resolution can lead to persistent p53 activation and chronic pathologies.
Key Genes Involved in GO:0043518 negative regulation of DNA damage response, signal transduction by p53 class mediator
The following genes and proteins are experimentally implicated in the negative regulation of p53-mediated DNA damage signaling, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HIC1 | Transcriptional repressor that silences p53 target genes | SNPs in HIC1 affect p53 regulation and cancer risk |
| CAMK1 | Calcium/calmodulin-dependent protein kinase involved in phosphoinositide signaling | Modulates protein sorting and transport in HCC, potentially impacting p53 |
| MDM2 | E3 ubiquitin ligase that targets p53 for degradation | Key negative regulator of p53 stability |
| ATM | DNA damage sensor kinase that activates p53 | Upstream activator, its downregulation reduces p53 signaling |
| ATR | DNA damage sensor kinase that activates p53 | Similar to ATM, part of the activation cascade |
| CDKN1A (p21) | p53 target gene that induces cell cycle arrest | Its repression is a marker of negative regulation |
| TP53 | Tumor suppressor transcription factor | Central to the pathway, subject to negative regulation |
| CtBP | Corepressor recruited by HIC1 | Mediates transcriptional repression of p53 targets |
| N-CoR | Nuclear receptor corepressor | Part of HIC1 repressor complex |
| SIRT1 | Deacetylase that deacetylates p53 | Reduces p53 transcriptional activity |
| PI3K | Phosphoinositide 3-kinase | Involved in CAMK1 signaling network |
| AKT | Kinase that phosphorylates MDM2 | Enhances p53 degradation |
| WIP1 (PPM1D) | Phosphatase that inactivates ATM/ATR | Negatively regulates DNA damage response |
| BRCA1 | DNA repair protein that also modulates p53 | Its loss alters p53 signaling |
| ESR1 | Estrogen receptor, linked to breast cancer gene expression | Associated with DNA damage response profiles |
| HER2 | Receptor tyrosine kinase, breast cancer marker | May influence p53 signaling via downstream pathways |
| CCND1 | Cyclin D1, cell cycle regulator | Its expression correlates with DNA damage response genes |
How Is negative regulation of DNA damage response, signal transduction by p53 class mediator Regulated?
The negative regulation of p53 signaling is itself tightly controlled. HIC1 expression can be epigenetically silenced by promoter hypermethylation, removing a key brake on p53. Additionally, kinases such as AKT phosphorylate MDM2, enhancing its ability to degrade p53. Phosphatases like WIP1 dephosphorylate ATM and p53, reducing the DNA damage signal. In breast cancer, gene expression profiling reveals that hormonal and growth factor pathways (e.g., ESR1, HER2) can modulate DNA damage response networks, indirectly affecting p53 negative regulation. In hepatocellular carcinoma, CAMK1 phosphoinositide signaling intersects with protein sorting and transport, potentially influencing p53 subcellular localization.
negative regulation of DNA damage response, signal transduction by p53 class mediator and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HIC1 | Breast cancer, tumor suppression | HIC1 knockout and point-mutation cell lines |
| CAMK1 | Hepatocellular carcinoma | CAMK1 overexpression and knockout in HCC cells |
| TP53 | Li-Fraumeni syndrome, multiple cancers | TP53 knock-in mutations in cell lines |
| MDM2 | Amplified in sarcomas and other cancers | MDM2 overexpression and knockout models |
| ESR1 | Breast cancer risk and progression | ESR1 mutant knock-in breast cancer cells |
Cancer
Dysregulation of GO:0043518 is a hallmark of many cancers. Loss of HIC1-mediated repression leads to unchecked p53 target gene expression or, paradoxically, allows cells with damaged DNA to survive if p53 is inactivated. In breast cancer, gene expression profiles associated with chemical risk factors show altered DNA damage response pathways, suggesting that negative regulation of p53 contributes to susceptibility. In hepatocellular carcinoma, CAMK1 signaling networks may disrupt normal p53 regulation, promoting tumor progression.
Neurodegeneration
While direct evidence is limited, excessive p53 activity is implicated in neuronal death after DNA damage. Negative regulators such as HIC1 or MDM2 may protect neurons by dampening p53 signaling; their dysfunction could contribute to neurodegenerative conditions.
Aging and Senescence
The balance between p53 activation and negative regulation influences cellular senescence. Reduced negative regulation can accelerate aging by promoting chronic senescence, whereas enhanced negative regulation may allow damaged cells to persist, increasing cancer risk.
From negative regulation of DNA damage response, signal transduction by p53 class mediator-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does HIC1 loss enhance p53-mediated apoptosis? | HIC1 knockout cell line |
| How do HIC1 SNPs affect p53 target gene repression? | Point-mutation knock-in of HIC1 variants |
| Can CAMK1 modulate p53 localization in HCC? | CAMK1 overexpression and knockout in HepG2 cells |
| What is the effect of MDM2 amplification on p53 stability? | MDM2 overexpression in cancer cell lines |
| Does ESR1 status influence DNA damage response gene expression? | ESR1 knock-in and knockout breast cancer models |
| Which genes negatively regulate p53 in a genome-wide screen? | CRISPR library screening in p53 reporter cells |
How to Study the negative regulation of DNA damage response, signal transduction by p53 class mediator Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Loss-of-function effects on p53 signaling | Identify negative regulators |
| RNA-seq | Transcriptional changes in p53 target genes | Profile DNA damage response networks |
| Proteomics | Protein abundance and modifications | Quantify p53 stability and interactions |
| Phosphoproteomics | Phosphorylation events | Map signaling cascades |
| ChIP-seq | DNA binding of p53 and corepressors | Locate repressed promoters |
| Live-cell imaging | p53 dynamics and localization | Study feedback loops |
| Bioinformatics | Gene expression correlation and pathway analysis | Link SNPs to disease risk |
| CAMK1 signaling assays | Kinase activity and protein transport | Investigate HCC-specific regulation |
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify genes whose loss or gain affects p53-mediated DNA damage responses. For example, screens in cells expressing p53 reporters can uncover novel negative regulators like HIC1.
Transcriptomics and Bioinformatics
RNA-seq and computational analysis of gene expression profiles from patient cohorts or cell lines can reveal networks associated with negative regulation of p53. Studies of breast cancer risk factors have used such approaches to link chemical exposures to DNA damage response gene signatures.
Proteomics and Phosphoproteomics
Mass spectrometry-based proteomics can quantify p53 post-translational modifications and interactors, identifying negative regulators such as MDM2 and phosphatases.
Imaging and Reporter Assays
Live-cell imaging of p53 dynamics using fluorescent reporters allows real-time monitoring of negative regulation. For instance, p53-MDM2 feedback loops can be visualized to study oscillation damping.
How CRISPR Can Be Used to Study GO:0043518 negative regulation of DNA damage response, signal transduction by p53 class mediator
Knockout
CRISPR knockout of negative regulators such as HIC1 or MDM2 can be used to assess their role in p53 signaling. For example, HIC1 knockout cells show enhanced p53 target gene expression and increased sensitivity to DNA damage.
Point Mutation
Introducing specific SNPs found in HIC1 or other genes via CRISPR point mutation allows functional testing of variants identified in computational analyses. This helps determine whether a SNP alters negative regulation of p53.
Knock-in
Knock-in of tagged versions of p53 or its regulators (e.g., GFP-p53) enables live-cell imaging and proteomic studies. Knock-in of disease-associated mutations (e.g., in TP53) can model cancer predisposition.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can elevate levels of negative regulators like MDM2 or CAMK1 to study their impact on p53 signaling and DNA damage response.
How EDITGENE Supports negative regulation of DNA damage response, signal transduction by p53 class mediator Research
Researchers studying negative regulation of DNA damage response, signal transduction by p53 class mediator-related genes often need to determine whether a candidate gene is causally involved in dampening p53 signaling. EDITGENE provides a comprehensive suite of CRISPR services to enable such functional studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of DNA damage response, signal transduction by p53 class mediator research.
Frequently Asked Questions About negative regulation of DNA damage response, signal transduction by p53 class mediator
What is GO:0043518?
GO:0043518 is a Gene Ontology term for the biological process that negatively regulates the p53-mediated DNA damage response, effectively putting a brake on p53 signaling.
What genes are involved in negative regulation of p53 DNA damage response?
Key genes include HIC1, MDM2, CAMK1, SIRT1, and WIP1, among others.
How does HIC1 regulate p53?
HIC1 is a transcriptional repressor that recruits corepressors to p53 target genes, reducing their expression and dampening the DNA damage response.
Why is negative regulation of p53 important in cancer?
It prevents excessive cell death and allows damaged cells to survive; its dysregulation can promote tumorigenesis or resistance to therapy.
What experimental models are used to study GO:0043518?
CRISPR knockout, point mutation, knock-in, overexpression cell lines, and library screening are commonly used.
Can CRISPR screening identify new negative regulators of p53?
Yes, genome-wide CRISPR screens have uncovered genes like HIC1 that negatively regulate p53 signaling.
What is the role of CAMK1 in p53 regulation?
CAMK1 phosphoinositide signaling influences protein sorting and transport in hepatocellular carcinoma, potentially modulating p53 localization and activity.
How is negative regulation of p53 linked to breast cancer?
Gene expression profiles in breast cancer show altered DNA damage response networks, and SNPs in regulators like HIC1 may affect risk.
What methods measure p53 negative regulation?
RNA-seq, proteomics, ChIP-seq, live-cell imaging, and bioinformatics are used to assess p53 activity and its regulators.
How can EDITGENE help study GO:0043518?
EDITGENE offers knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to dissect p53 negative regulation.
Conclusion
GO:0043518 represents a critical layer of control in the DNA damage response, ensuring that p53 activity is appropriately restrained. Dysregulation of this process contributes to cancer and other diseases, making it a promising therapeutic target. Continued research using advanced CRISPR models and multi-omics approaches will further elucidate the molecular players and their clinical potential.
References
- 1. Annanya A et al.. 2024. Computational Analysis of Single Nucleotide Polymorphisms in Human HIC1 Gene.. Cureus 16(3):e56664 PMID: 38646326
- 2. Achebouche R et al.. 2025. Assessment of chemical risk factor for breast cancer based on gene expression profiles.. Sci Rep 15(1):43983 PMID: 41408116
- 3. Wang L et al.. 2014. CAMK1 phosphoinositide signal-mediated protein sorting and transport network in human hepatocellular carcinoma (HCC) by biocomputation.. Cell Biochem Biophys 70(2):1011-6 PMID: 24825433
